Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Epidemiological impact of a syphilis vaccine: a simulation study.

Epidemiology and infection·2016

Same author

Fidelity of Nucleotide Incorporation by the RNA-Dependent RNA Polymerase from Poliovirus.

The Enzymes·2016

Same author

Synthesis of Dipeptides with Ψ[CH(2)0] Amide Bond Mimetics.

Methods in molecular medicine·2011

Same author

Cyclic Aromatic Amino Acids with Constrained χ(1) and χ (2) Dihedral Angles.

Methods in molecular medicine·2011

Same author

Characterization of a novel family of fibronectin-binding proteins with M23 peptidase domains from Treponema denticola.

Molecular oral microbiology·2010

Same author

Identification of the oriI-binding site of poliovirus 3C protein by nuclear magnetic resonance spectroscopy.

Journal of virology·2008

Search research articles

Related Experiment Video

Updated: May 14, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

D G Cordek¹, J T Bechtel, A T Maynard

¹Department of Biochemistry and Molecular Biology, The Pennsylvania State University, University Park, Pennsylvania, USA.

Drugs of the Future

|February 5, 2013

Summary

New Hepatitis C virus (HCV) treatments targeting the NS5A protein have evolved from monomers to potent dimeric compounds. These advancements offer improved efficacy and broader genotype coverage for HCV infection.

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

Related Experiment Videos

Last Updated: May 14, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

Area of Science:

Hepatology
Virology
Medicinal Chemistry

Background:

Hepatitis C virus (HCV) infection affects over 3% of the global population, increasing risks of cirrhosis and liver cancer.
Current treatments like pegylated interferon alfa and ribavirin have limitations in tolerability and efficacy, particularly against genotype 1.
Emerging direct-acting antivirals target viral proteins, including NS5A, a key factor in HCV replication.

Purpose of the Study:

To describe the evolution of small-molecule inhibitors targeting the Hepatitis C virus NS5A protein.
To highlight the development from monomeric to dimeric compounds with enhanced potency and broader genotype activity.
To present recent clinical data and insights into the binding mechanisms of NS5A inhibitors.

Main Methods:

Drug design and development of small-molecule inhibitors targeting NS5A.
Evaluation of inhibitor efficacy across various Hepatitis C virus genotypes.
Analysis of clinical data and investigation of potential binding interactions with NS5A.

Main Results:

Development of highly potent dimeric NS5A inhibitors from earlier monomeric designs.
Demonstrated efficacy of these dimeric compounds against multiple Hepatitis C virus genotypes.
Insights into the binding mechanisms of NS5A inhibitors, considering NS5A dimerization.

Conclusions:

Small-molecule inhibitors targeting NS5A have significantly advanced, with dimeric compounds showing superior efficacy.
These novel inhibitors represent a promising therapeutic strategy for Hepatitis C virus infection, offering broader genotype coverage.
Further research into NS5A inhibitor binding and clinical application is warranted for improved Hepatitis C treatment outcomes.